Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib in Recurrent and/or Metastatic Head and Neck Cancer
NCT00098631Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2004
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate up to 6 years and Progression-Free Survival up to 6 years. Started Oct 2004; status: completed.
02
Drugs
lapatinib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00098631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00098631.